Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "THOR Study - Erdafitinib vs. Pembrolizumab in Pretreated Patients With Advanced/Metastatic Urothelial Cancer With Select FGFR Alterations"

164 views
November 3, 2023
0 Comments
Login to view comments. Click here to Login
Genitourinary